Noninvasive Urine-Based Tests to Diagnose or Detect Recurrence of Bladder Cancer

Charpentier, Marine; Gutierrez, Charly; Guillaudeux, Thierry; Verhoest, G.; Pedeux, Rémy

doi:10.3390/cancers13071650

Cited by 24 publications

(21 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these methods fall short of expectations due to high cost, poor cytology sensitivity, high invasiveness of cystoscopy, and significant inter and intra-observer variability in tumor stage and grade interpretation (Su et al 2019 ). The food and drug administration (FDA) has approved urinary biomarkers include BTA Stat, BTA Trak, nuclear matrix protein 22 (NMP22), UroVysion, ubiquitin C (UBC), and other assays such as immunocytochemistry (uCyt+ and DD23) and fluorescence in situ hybridization (FISH) being widely used for patient follow-up, though with lesser potency in low-grade cancer detection (Charpentier et al 2021 ). BCa is generally managed with classical approaches such as chemotherapy, surgery, or radiation (Dobruch and Oszczudłowski 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic potential clustered miRNAs in bladder cancer

et al. 2022

View full text Add to dashboard Cite

At specific genomic loci, miRNAs are in clusters and their association with copy number variations (CNVs) may exhibit abnormal expression in several cancers. Hence, the current study aims to understand the expression of miRNA clusters residing within CNVs and the regulation of their target genes in bladder cancer. To achieve this, we used extensive bioinformatics resources and performed an integrated analysis of recurrent CNVs, clustered miRNA expression, gene expression, and drug–gene interaction datasets. The study identified nine upregulated miRNA clusters that are residing on CNV gain regions and three miRNA clusters (hsa-mir-200c/mir-141, hsa-mir-216a/mir-217, and hsa-mir-15b/mir-16-2) are correlated with patient survival. These clustered miRNAs targeted 89 genes that were downregulated in bladder cancer. Moreover, network and gene enrichment analysis displayed 10 hub genes (CCND2, ETS1, FGF2, FN1, JAK2, JUN, KDR, NOTCH1, PTEN, and ZEB1) which have significant potential for diagnosis and prognosis of bladder cancer patients. Interestingly, hsa-mir-200c/mir-141 and hsa-mir-15b/mir-16-2 cluster candidates showed significant differences in their expression in stage-specific manner during cancer progression. Downregulation of NOTCH1 by hsa-mir-200c/mir-141 may also sensitize tumors to methotrexate thus suggesting potential chemotherapeutic options for bladder cancer subjects. To overcome some computational challenges and reduce the complexity in multistep big data analysis, we developed an automated pipeline called CmiRClustFinder v1.0 (https://github.com/msls-bioinfo/CmiRClustFinder_v1.0), which can perform integrated data analysis of 35 TCGA cancer types.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic potential clustered miRNAs in bladder cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A crucial current issue is the capability to detect BCa easily and early using less invasive methods and, ideally, with markers showing high sensitivity and specificity [ 100 ]. Molecular markers, such as circulating mRNAs, in urine and blood could offer promising sources to gain comprehension of BCa and its associated micro- and macro-environment.…”

Section: Discussionmentioning

confidence: 99%

An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer

Sarafidis

Lambrou

Zoumpourlis

et al. 2022

Cancers

View full text Add to dashboard Cite

Bladder cancer (BCa) is one of the most prevalent cancers worldwide and accounts for high morbidity and mortality. This study intended to elucidate potential key biomarkers related to the occurrence, development, and prognosis of BCa through an integrated bioinformatics analysis. In this context, a systematic meta-analysis, integrating 18 microarray gene expression datasets from the GEO repository into a merged meta-dataset, identified 815 robust differentially expressed genes (DEGs). The key hub genes resulted from DEG-based protein–protein interaction and weighted gene co-expression network analyses were screened for their differential expression in urine and blood plasma samples of BCa patients. Subsequently, they were tested for their prognostic value, and a three-gene signature model, including COL3A1, FOXM1, and PLK4, was built. In addition, they were tested for their predictive value regarding muscle-invasive BCa patients’ response to neoadjuvant chemotherapy. A six-gene signature model, including ANXA5, CD44, NCAM1, SPP1, CDCA8, and KIF14, was developed. In conclusion, this study identified nine key biomarker genes, namely ANXA5, CDT1, COL3A1, SPP1, VEGFA, CDCA8, HJURP, TOP2A, and COL6A1, which were differentially expressed in urine or blood of BCa patients, held a prognostic or predictive value, and were immunohistochemically validated. These biomarkers may be of significance as prognostic and therapeutic targets for BCa.

show abstract

“…Immunotherapy is limited as it inhibits non-muscular and muscular invasive BC at the laboratory level ( Schneider et al, 2019 ; Witjes et al, 2021 ). For patients with non-muscle invasive tumors (NMIBC), transurethral resection combined with postoperative bladder perfusion chemotherapy or BCG treatment strategies is usually adopted ( Charpentier et al, 2021 ; Li et al, 2021e ). However, 20–30% of NMIBC patients will progress to muscle invasive bladder cancer (MIBC), and 50% will develop distant metastases within 2 years of radical surgery ( Jiang et al, 2021a ; Liu et al, 2021a ).…”

Section: Introductionmentioning

confidence: 99%

Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer

Liu

2022

Front. Genet.

View full text Add to dashboard Cite

N6-methyladenosine (m6A) is a dynamic, reversible post-transcriptional modification, and the most common internal modification of eukaryotic messenger RNA (mRNA). Considerable evidence now shows that m6A alters gene expression, thereby regulating cell self-renewal, differentiation, invasion, and apoptotic processes. M6A methylation disorders are directly related to abnormal RNA metabolism, which may lead to tumor formation. M6A methyltransferase is the dominant catalyst during m6A modification; it removes m6A demethylase, promotes recognition by m6A binding proteins, and regulates mRNA metabolic processes. Bladder cancer (BC) is a urinary system malignant tumor, with complex etiology and high incidence rates. A well-differentiated or moderately differentiated pathological type at initial diagnosis accounts for most patients with BC. For differentiated superficial bladder urothelial carcinoma, the prognosis is normally good after surgery. However, due to poor epithelial cell differentiation, BC urothelial cell proliferation and infiltration may lead to invasive or metastatic BC, which lowers the 5-years survival rate and significantly affects clinical treatments in elderly patients. Here, we review the latest progress in m6A RNA methylation research and investigate its regulation on BC occurrence and development.

show abstract

Noninvasive Urine-Based Tests to Diagnose or Detect Recurrence of Bladder Cancer

Cited by 24 publications

References 117 publications

Diagnostic and prognostic potential clustered miRNAs in bladder cancer

Diagnostic and prognostic potential clustered miRNAs in bladder cancer

An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer

Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer

Contact Info

Product

Resources

About